Together, αβ and γδ T cells elicited superior control of established ovarian cancer xenografts in response to these BTN3A1 antibodies, in a manner that was superior to PD-1 checkpoint therapy and dependent on the expression of a second butyrophilin (BTN2A1) [3]. The gene discussed is BTN3A1; the disease is ovarian carcinoma.